Antimalarial immune response to liver-stage P. falciparum Infections and Infestations
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 years and above 2. Scheduled for partial liver resection for underlying disease 3. Signed written informed consent
Exclusion criteria
Exclusion criteria: 1. Known receipt of immunosuppressive or cytostatic agents within the past 3 months, except the use of topical and inhaled steroids 2. Known human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection, or other known clinically-relevant immunodeficient state
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured at the surgery visit: 1. Recognition of P. falciparum-infected hepatocytes by CSP-specific cytolytic CD8+ T cells and hepatic and peripheral innate/innate-like lymphocytes measured using flow cytometry 2. Killing of P. falciparum-infected hepatocytes by CSP-specific cytolytic CD8+ T cells and hepatic and peripheral innate/innate-like lymphocytes measured using fluorescence microscopy | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at the surgery visit: 1. Recognition and killing of P. falciparum-infected hepatocytes by CSP-specific cytolytic CD8+ T cell line measured using flow cytometry and fluorescence microscopy 2. Differences in recognition and killing of P. falciparum-infected hepatocytes between liver-resident and peripheral lymphocytes measured using flow cytometry and fluorescence microscopy 3. The individual lymphocyte (sub-)populations which contribute to the recognition and killing of P. falciparum-infected hepatocytes, identified using flow cytometry | — |
Countries
Netherlands